The China-to-global biotech corridor.
Chinese innovation now feeds the global development pipeline. We help originators and acquirers move assets across that corridor with diligence, discretion, and deal structures that hold up on both sides.
Four ways to work the corridor.
Whether you are sourcing differentiated assets out of China or routing a domestic program to global markets, the entry point is the same conversation. The path depends on which side of the corridor you start from.
Source In
Identify and acquire rights to clinical-stage assets emerging from Chinese biotech for Western development and commercialization.
- Asset mapping
- Scientific diligence
- Rights structuring
Route Out
Position domestic programs for qualified global partners, with packages and terms built for international scrutiny.
- Buyer mapping
- Data-room build
- Terms negotiation
Co-Develop
Stand up cross-border alliances that share development, manufacturing, and commercial reach across both regions.
- Alliance design
- Cost & risk sharing
- Territory split
Spin Out
Carve corridor assets into purpose-built entities backed by global capital and dedicated leadership.
- Carve-out structuring
- Capital syndication
- Governance design
Why the corridor matters now.
The center of gravity in early innovation has shifted. Reading that shift correctly is the difference between a sourced opportunity and a missed one.
Innovation density has moved
Clinical-stage pipelines out of China now rival established hubs in volume and, increasingly, in quality. The supply of licensable, differentiated assets has expanded faster than most Western pipelines can absorb it.
Valuation gaps create opportunity
Assets that command premium economics in Western markets are frequently available on more favorable terms at the source. Disciplined diligence turns that gap into durable value rather than a hidden liability.
Cross-border execution is the constraint
The science is rarely the bottleneck. Regulatory translation, IP integrity, manufacturing transfer, and governance across jurisdictions are where corridor deals stall – or fail quietly after signing.
Trust is the scarce asset
Counterparties on both sides need a partner who is credible in both markets and answerable to neither. We sit in the middle, NDA-first, aligning incentives so the deal serves the asset rather than either flag.
The corridor at a glance.
A working view of where deal energy concentrates. Indicative of the flow we advise across, not a published index.
| Direction | China-out leads volume; selective China-in for late-stage Western assets |
|---|---|
| Hottest modalities | ADCs · bispecifics · cell & gene · GLP-1 combinations |
| Typical stage | Preclinical lead to Phase 2, with Phase 3 carve-outs on demand |
| Common structure | Ex-China license · global rights buyout · regional co-development |
| Deal size | $25M – $1B+ in committed economics, milestone-weighted |
| Typical timeline | 4–9 months · term-sheet to close, partner-led throughout |
The next decade of medicines will be sourced where the science is densest and built where the market is deepest – and the firms that win will be the ones fluent in moving assets between the two.
PharmaSync
How we de-risk a corridor asset.
Six lenses applied to every cross-border opportunity before a term sheet is drafted. Each one has killed a deal that looked clean on the surface.
Scientific integrity
Independent review of preclinical and clinical data, source documents, and reproducibility – read with Western regulatory standards in mind.
IP & ownership
Verification of patent estate, inventorship, freedom to operate, and clean chain of title across jurisdictions.
Regulatory translation
Mapping of local filings to FDA and EMA pathways, with a candid view of what data will and will not transfer.
Manufacturing & supply
Assessment of CMC maturity, comparability, and the feasibility of technology transfer to qualified sites.
Counterparty & structure
Background on the originator, cap-table clarity, and a deal structure that survives currency, tax, and control questions.
Geopolitical resilience
Stress-testing against trade, export-control, and policy shifts so the asset holds value regardless of the headlines.
From the corridor desk.
Field notes on the China-to-global flow, written for principals who need signal over noise.